Dr. Odisho on a Risk Prediction Model in Renal Cell Carcinoma

Video

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma.

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma (RCC).

Though risk prediction models are generally prevalent in all of medicine and its corresponding research, they can be difficult to apply in a real world setting with patients and the community, Odisho explains.

Odisho and his colleagues thus set out to develop an interactive tool that can make the application of these nomograms more user-friendly. They used the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria, which is validated for patients with metastatic RCC, and created an interactive visualization that displays key criteria and allows a user to make selections and see results in real time. Not only can the user see each of the individual risk predictive factors, but he can also see each individual patient within a cohort, explains Odisho.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine